Ketogenic enzymes (KE)

Ketogenic enzymes represent a group of metabolic catalysts responsible for the synthesis (ketogenesis) and utilization (ketolysis) of ketone bodies, primarily in the liver and extrahepatic tissues like the brain and heart. The pathway is centered around the rate-limiting enzyme 3-hydroxy-3-methylglutaryl-CoA synthase 2 (HMGCS2), which converts acetyl-CoA into HMG-CoA, followed by the actions of HMG-CoA lyase (HMGCL) and beta-hydroxybutyrate dehydrogenase (BDH1) (Source: PubMed, PMID: 24561254). These enzymes are critical during periods of fasting or carbohydrate restriction, providing an alternative energy source to glucose. In therapeutic contexts, modulating these enzymes is explored for treating refractory epilepsy through the ketogenic diet, managing type 2 diabetes, and potentially inhibiting tumor growth in cancers that lack ketolytic capacity (Source: StatPearls, NBK493179). Pharmacological targeting often involves PPAR-alpha agonists that upregulate enzyme expression or inhibitors that disrupt specific steps in the pathway to alter systemic energy metabolism (Source: NIH, PMC6627766).

Other names

Ketogenesis enzymesKetone body metabolic enzymesHMG-CoA pathway enzymesKetolytic enzymes

Modulation of enzyme expression via PPAR-alpha activation, competitive inhibition of specific pathway steps, or substrate availability alteration to shift metabolic flux toward or away from ketone body production.